NCT01620554View on ClinicalTrials.gov

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Obstructive Sleep ApnoeaExcessive Daytime Sleepiness
Interventions
DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

Placebo

1 capsule per week during 2 weeks

Trial Locations (1)

38043

CHU de Grenoble, Grenoble

Sponsors

Lead Sponsor

Bioprojet
All Listed Sponsors
lead

Bioprojet

OTHER